Anna Jonášová (Anna Jonasova)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 7

Top Topics

Acute Myeloid Leukemia

Top Venues

International journal of cancer

Blood cancer journal

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Monika Kaisrlikova, David Kundrat, Pavla Koralkova, Iva Trsova, Zuzana Lenertova, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Jitka Vesela, Martin Vostry, Radka Simeckova, Marketa Stastna Markova, Marie Lauermannova, Anna Jonášová, Jaroslav Cermak, Vladimír Divoký, Monika Belickova
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms. International journal of cancer 154 (9) (2024)
Monika Kaisrlikova, David Kundrat, Pavla Koralkova, Iva Trsova, Zuzana Lenertova, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Jitka Vesela, Martin Vostry, Radka Simeckova, Marketa Stastna Markova, Marie Lauermannova, Anna Jonášová, Jaroslav Cermak, Vladimír Divoký, Monika Belickova
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms. International journal of cancer 154 (9) (2024)
Monika Kaisrlikova, David Kundrat, Pavla Koralkova, Iva Trsova, Zuzana Lenertova, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Jitka Vesela, Martin Vostry, Radka Simeckova, Marketa Stastna Markova, Marie Lauermannova, Anna Jonášová, Jaroslav Cermak, Vladimír Divoký, Monika Belickova
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms. International journal of cancer (2024)
Monika Kaisrlikova, Jitka Vesela, David Kundrat, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Vladimír Divoký, Marek Jedlicka, Jan Fric, Jiri Klema, Dana Mikulenkova, Marketa Stastna Markova, Marie Lauermannova, Jolana Mertova, Jacqueline Soukupova Maaloufova, Anna Jonášová, Jaroslav Cermak, Monika Belickova
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia 36 (7) (2022)
Anne-Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonášová, Regina Herbst, Jose Miguel Torregrosa Diaz, Benoit De Renzis, Katharina S Götze, Marie-Luise Huetter-Kroenke, Marie-Pierre Gourin, Borhane Slama, Sophie Dimicoli-Salazar, Pascale Cony-Makhoul, Kamel Laribi, Sophie Park, Katja Jersemann, Dorothea Schipp, Klaus H Metzeler, Oliver Tiebel, Katja Sockel, Silke Gloaguen, Anna Mies, Fatiha Chermat, Christian Thiede, Rosa Sapena, Richard F Schlenk, Pierre Fenaux, Uwe Platzbecker, Lionel Ades
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO. Leukemia 36 (10) (2022)
Tomáš Stopka, Lubomír Minařík, Nina Dusilková, Michal Pešta, Vojtěch Kulvait, Martin Špaček, Zuzana Zemanová, Marta Kalousová, Anna Jonášová
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. Blood cancer journal 12 (7) (2022)
Alena Moudra, Lubomir Minarik, Marketa Vancurova, Jiri Bartek, Zdenek Hodny, Anna Jonášová
NQO1*2 polymorphism predicts overall survival in MDS patients. British journal of haematology 184 (2) (2018)